Browsing Category

Upcoming conference

Articles Banking Featured News Infographics Past Conference Uncategorized Webinar

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

2026-08-12T11:30:00Z

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

2026-08-12T11:30:00Z

Record second quarter 2026 revenue increased 35% to $17.1 million, compared with Q2 2025

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

2026-08-12T11:30:00Z

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

2026-08-12T11:30:00Z

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been...

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

2026-08-12T11:30:00Z

Initiated global PERFORMA Phase 3 trial in MASH

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2026-08-12T11:30:00Z

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026

Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality

2026-08-12T11:12:02Z

COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness...

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

2026-08-12T11:08:47Z

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

2026-08-12T11:05:00Z

– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

2026-08-12T11:05:00Z

REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare...

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2026-08-12T11:00:00Z

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028

Kamada Announces Planned Transition of Chief Financial Officer

2026-08-12T11:00:00Z

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare...

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

2026-08-12T11:00:00Z

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta...

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

2026-08-12T11:00:00Z

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

2026-08-12T11:00:00Z

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with...

Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis

2026-08-12T11:00:00Z

NAPLES, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that...

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

2026-08-12T11:00:00Z

BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms...

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

2026-08-12T11:00:00Z

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs

Persephone Biosciences Publishes Largest U.S. Clinical Study of an Infant Synbiotic in Pediatric Research, Expanding Clinical Evidence for Its Infant Synbiotics

2026-08-12T11:00:00Z

Publication reports results from the largest U.S. randomized trial evaluating a synergistic Bifidobacterium-HMO synbiotic in infants and toddlers, demonstrating safety, successful gut colonization and biologically meaningful microbiome changes.

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

2026-08-12T11:00:00Z

On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

2026-08-12T11:00:00Z

– Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study –

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-08-12T10:50:00Z

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living...

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

2026-08-12T10:05:00Z

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

2026-08-12T10:00:00Z

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly...

Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases

2026-08-12T09:00:00Z

COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing the use of SNIPR001 in...

Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement

2026-08-12T08:00:00Z

Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform

BioPorto A/S to host an investor webcast on the results for the first half of 2026

2026-08-12T07:29:49Z

FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares

2026-08-12T01:10:17Z

FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

2026-08-12T00:01:00Z

GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...

Anteris Technologies Announces Results for the Second Quarter of 2026

2026-08-11T23:00:00Z

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing,...

The Future of Finance: Navigating Innovation, Risk, and Global Growth

Fintech Horizons 2025: Shaping the Future of Digital Finance

“The Future of Fintech—Innovation, Regulation & Global Trends”

Upcoming conference